Anticoagulation in special patient populations: Are special dosing considerations required?

Franklin Michota, MD
Section of Hospital Medicine, Department of General Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

Geno Merli, MD
Division of Internal Medicine, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA

Correspondence: Franklin Michota, MD, Department of General Internal Medicine, E13, Cleveland Clinic Foundation, Cleveland, OH 44195; michotf@ccf.org

Dr. Michota has received grant/research support from Sanofi-Aventis and is a consultant for Sanofi-Aventis and Pfizer.

Dr. Merli has received grant/research support from Sanofi-Aventis, AstraZeneca, and Bristol-Myers Squibb, and is a consultant for and on the speakers' bureaus of Sanofi-Aventis and AstraZeneca.

Franklin Michota, MD
Section of Hospital Medicine, Department of General Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

Geno Merli, MD
Division of Internal Medicine, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA

Correspondence: Franklin Michota, MD, Department of General Internal Medicine, E13, Cleveland Clinic Foundation, Cleveland, OH 44195; michotf@ccf.org

Dr. Michota has received grant/research support from Sanofi-Aventis and is a consultant for Sanofi-Aventis and Pfizer.

Dr. Merli has received grant/research support from Sanofi-Aventis, AstraZeneca, and Bristol-Myers Squibb, and is a consultant for and on the speakers' bureaus of Sanofi-Aventis and AstraZeneca.

Franklin Michota, MD
Section of Hospital Medicine, Department of General Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

Geno Merli, MD
Division of Internal Medicine, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA

Correspondence: Franklin Michota, MD, Department of General Internal Medicine, E13, Cleveland Clinic Foundation, Cleveland, OH 44195; michotf@ccf.org

Dr. Michota has received grant/research support from Sanofi-Aventis and is a consultant for Sanofi-Aventis and Pfizer.

Dr. Merli has received grant/research support from Sanofi-Aventis, AstraZeneca, and Bristol-Myers Squibb, and is a consultant for and on the speakers' bureaus of Sanofi-Aventis and AstraZeneca.